Exploring the MRI and Clinical Features of P53-Mutated Hepatocellular Carcinoma
Jingfei Weng,Yuyao Xiao,Jing Liu,Xiaohua Liu,Yuqing He,Fei Wu,Xiaoyan Ni,Chun Yang
DOI: https://doi.org/10.2147/jhc.s462979
2024-09-01
Journal of Hepatocellular Carcinoma
Abstract:Jingfei Weng, 1, 2, &ast Yuyao Xiao, 1, &ast Jing Liu, 3, &ast Xiaohua Liu, 4 Yuqing He, 2 Fei Wu, 1 Xiaoyan Ni, 1 Chun Yang 1 1 Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; 2 Department of Radiology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, People's Republic of China; 3 Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; 4 Department of Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chun Yang; Xiaoyan Ni, Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China, Tel +86 18702135336 ; +86 15201803582, Email ; Purpose: To study the MRI features (based on LI-RADS) and clinical characteristics of P53-mutated hepatocellular carcinoma (HCC) patients. Patients and Methods: This study enrolled 344 patients with histopathologically confirmed HCC (P53-mutated group [n = 196], non-P53-mutated group [n = 148]). We retrospectively evaluated the preoperative MRI features, clinical and pathologic features of the lesions and assigned each lesion according to the LI-RADS. MRI findings, clinical features, and pathologic findings were compared using the Student's t test, χ 2 test, and multivariable regression analysis. Results: Most HCC patients were categorized as LR-5. On multivariate analysis, the Edmondson–Steiner grade (odds ratio, 2.280; 95% CI: 1.268, 4.101; p = 0.006) and rim enhancement (odds ratio, 2.517; 95% CI: 1.095, 5.784; p = 0.030) were found to be independent variables associated with P53-mutated HCC. In the group of HCC lesions with the largest tumor diameter (LTD) greater than or equal to 10mm and less than or equal to 20mm, enhancing capsule was an independent predictor of P53-mutated HCC (odds ratio, 6.200; 95% CI: 1.116, 34.449; p = 0.037). Among the HCC lesions (20 mm ˂ LTD ≤ 50 mm), corona enhancement (odds ratio, 2.102; 95% CI: 1.022, 4.322; p = 0.043) and nodule-in-nodule architecture (odds ratio, 2.157; 95% CI: 1.033, 4.504; p = 0.041) were found to be independent risk factors for P53 mutation. Among the HCC lesions (50 mm ˂ LTD ≤ 100 mm), diameter (odds ratio, 1.035; 95% CI: 1.001, 1.069; p = 0.044) and AFP ≥ 400 (ng/mL) (odds ratio, 3.336; 95% CI: 1.052, 10.577; p = 0.041) were found to be independent variables associated with P53-mutated HCC. Conclusion: Poor differentiation and rim enhancement are potential predictive biomarkers for P53-mutated HCC, while HCCs of different diameters have different risk factors for predicting P53 mutations. Keywords: liver neoplasms, magnetic resonance imaging, P53-mutated More than 90% of primary liver cancers are hepatocellular carcinoma (HCC) and are predisposed to occur in patients with underlying chronic liver disease. 1 HCC has a high mortality rate, and the survival rate of patients with advanced HCC is very low. 2 HCC has a poor prognosis mainly because it is prone to vascular infiltration, metastasis and recurrence. 3 It is important for patients to be able to make preoperative predictions about the prognosis of hepatocellular carcinoma and to choose appropriate treatment options. Therefore, additional data about the pathogenesis of HCC are needed to investigate new and more effective treatments to improve the survival of HCC patients. P53 is an important tumor suppressor gene involved in the development of hepatocellular carcinoma, and it is closely related to cell cycle arrest, cellular regulation and cellular senescence. 4 While the wild-type P53 gene is a tumor suppressor gene, mutant P53 has oncogenic activity, this protein not only binds to wild-type P53 to form a complex and inhibit P53 gene function but also promotes abnormal cell proliferation and participates in tumor formation. 5 The most commonly mutated genes in hepatocellular carcinoma are TERT (promoter), TP53, CTNNB1, AXIN1, ARID1A , and ARID2 , whereas the chance of mutation occurring in other genes is less than 10%. 6 Enrichment of TP53 inactivating mutations promotes the onset of HCC proliferation, including in clinically aggressive tumors with poor differentiation and frequent vascular invasion. The mutation rate of the P53 gene in HCC patients is 31.5%, and the expression up-regulation is 35.0%. Moreover, P53 expression can lead to a poor progno -Abstract Truncated-
oncology